证券之星消息，截至2026年1月30日收盘，英科医疗(300677)报收于41.86元，上涨2.57%，换手率 2.51%，成交量11.71万手，成交额4.81亿元。 1月30日的资金流向数据方面，主力资金净流入1347.49万元，占总成交额2.8%，游资资金净流入 2536.19万元，占总成交额5.27%，散户资金净流出3883.69万元，占总成交额8.07%。 | 指标 | 英科医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 274.25亿元 | 111.02亿元 | 7 127 | | 净资产 | 184.67亿元 | 38.45亿元 | 4 127 | | 净利润 | 9.24亿元 | 2.1亿元 | 7 127 | | 市盈率(动) | 22.25 | 104.17 | 16 127 | | 市净率 | 1.51 | 4.04 | 18 127 | | 毛利率 | 23.7% | 50.94% | 117 127 | | 净利率 | 12.82% | 9.66% | 54 127 | | ROE | 5.19% | 0.43% | 5 ...

Core Viewpoint - Inke Medical announced that its controlling shareholder, Liu Fangyi, has completed the pledge registration and release procedures for part of his shares, indicating potential changes in shareholder structure and liquidity management [2] Group 1 - Liu Fangyi pledged 20,550,000 shares of Inke Medical [2] - Liu Fangyi released 6,460,000 shares from pledge [2]

每经头条（nbdtoutiao）——水贝黄金平台"杰我睿"兑付危机调查：40倍杠杆对赌，金价越涨平台越 亏！老板自称"还在深圳"，投资者：兑付方案本金打两折，无法接受 每经AI快讯，英科医疗1月29日晚间发布公告称，截至本公告日，刘方毅累计质押股数为2855万股，占 其所持股份比例为12.32%。 （记者 曾健辉） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 ...

证券代码：300677 证券简称：英科医疗 公告编号：2026-006 英科医疗科技股份有限公司 | 股东名称 | 是否为控股股东或 第一大股东及其一 | 本次解除质 | 占其所 | 占公司 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 押股数（股） | 持股份 | 总股本 | 起始日 | | 解除日期 | | 质权人 | | | 致行动人 | | 比例 | 比例 | | | | | | | | | 5,800,000 | 2.50% | 0.89% | 2025 年 | 02 | | | | | | | | | | 月 05 | 日 | | | | | 刘方毅 | 是 | | | | 2025 年 | 08 | 年 2026 1 | 月 | 国金证券资产管 | | | | 8,300,000 | 3.58% | 1.27% | 月 | | | | | | | | | | | 07 | 日 | | | | 关于控股股东部分股份质押及解除质押的公告 本公司及董事会全体成员保证公告内容真实、准确、完整 ...

证券代码：300677 证券简称：英科医疗 公告编号：2026-005 关于为子公司提供担保事项的进展公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 英科医疗科技股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日、2025 年 5 月 26 日分别召开的第四届董事会第二次（定期） 会议、第四届监事会第二次（定期）会议以及 2024 年度股东大会， 审议通过了《关于公司及子公司向银行申请授信额度及担保事项的议 案》。为满足公司及子公司的生产经营需要，公司及子公司拟向银行 等金融机构申请综合授信的额度以及金融衍生品交易风险限额的总 额（以下简称"授信额度"）不超过 360 亿元人民币，对其担保总额 不超过 360 亿元人民币，授权期限自公司 2024 年度股东大会审议通 过之日起至下一年度股东大会召开时止。具体内容详见刊登于巨潮资 讯网（www.cninfo.com.cn）的《关于公司及子公司向银行申请授信额 度及担保事项的公告》《2024 年度股东大会决议公告》（公告编号： 2025-046、2025-072）。 一、担保事项概述 江西英科医疗有 ...

Group 1 - The core viewpoint is that innovative drugs are expected to show significant excess returns in 2025, driven by continuous BD overseas expansion, excellent clinical data, and policy support [1] - The CXO sector is anticipated to experience substantial growth due to the recovery in demand and improved investment environment in the global pharmaceutical industry [1] - The report emphasizes the importance of focusing on new technologies, particularly bispecific antibodies, small nucleic acid drugs, AI healthcare, and brain-computer interface innovations [3] Group 2 - Domestic supply and demand are relatively stable, with national health expenditure showing a year-on-year growth of 4.7% from January to November 2025, marking a positive turnaround after two years of decline [2] - The medical insurance fund's income and expenditure growth rates continue to decline, with total income of 2.63 trillion yuan (+2.9%) and expenditure of 2.11 trillion yuan (+0.5%) from January to November [2] - The report suggests that the commercialization of new drug forms is entering a critical phase, with significant clinical data supporting the application of B-cell depletion therapies in autoimmune diseases [3] Group 3 - Investment recommendations include focusing on innovative overseas expansion and new technology directions, with suggested stocks such as Mindray Medical, WuXi AppTec, and others [4] - The report highlights the potential for explosive growth in the global market for brain-computer interfaces, supported by policy incentives and technological breakthroughs [3]

Group 1 - In the stock market, Yingke Medical experienced a decline of 5.78%, with a current share price of 42.20 yuan, a trading volume of 1.28 billion yuan, a turnover rate of 0.63%, and a total market capitalization of 27.648 billion yuan [1] - Yingke Medical Technology Co., Ltd. is located in Zibo City, Shandong Province, and was established on July 20, 2009, with its listing date on July 21, 2017. The company's main business includes three segments: personal protection (91.47% of revenue), rehabilitation care (4.75%), and other products (3.77%) [1] Group 2 - From the perspective of major fund holdings, Chunhou Fund has one fund heavily invested in Yingke Medical. The Chunhou Times Preferred Mixed A Fund (014235) held 12,000 shares in the fourth quarter, unchanged from the previous period, accounting for 2.84% of the fund's net value, making it the fourth-largest holding. The estimated floating loss today is approximately 31,100 yuan [2] - The Chunhou Times Preferred Mixed A Fund (014235) was established on January 27, 2022, with a latest scale of 14.6472 million yuan. Year-to-date returns are 6.65%, ranking 3,570 out of 8,861 in its category; the one-year return is 39.41%, ranking 3,052 out of 8,126; and since inception, the return is 2.31% [2]

Group 1 - The stock price of Yingke Medical (300677) closed at 44.79 yuan on January 26, 2026, with an increase of 2.56% and a turnover rate of 4.87% [1] - The trading volume was 226,500 shares, with a total transaction amount of 1.01 billion yuan [1] - On January 26, the net inflow of main funds was 61.63 million yuan, while retail investors experienced a net outflow of 58.76 million yuan [2] Group 2 - Yingke Medical provided a joint liability guarantee of 80 million yuan for its wholly-owned subsidiary, Anqing Yingke Medical, to apply for credit from CITIC Bank [1] - The total guarantee balance after this transaction is 1.065 billion yuan, which accounts for 5.86% of the company's latest net assets [1][2] - The cumulative guarantee credit balance is 1.602 billion yuan, representing 92.06% of the audited net assets [1]

Core Viewpoint - Inke Medical announced its total guarantee amount and credit balance, indicating a significant portion of its net assets is tied to guarantees [2] Group 1: Guarantee Information - As of the announcement date, the total guarantee amount for the company and its subsidiaries is 3,600,000,000 CNY [2] - The cumulative guarantee credit balance is 1,602,226,200 CNY, which includes the current amount, representing 92.06% of the company's most recent audited net assets [2] - There are no guarantees provided to entities outside the consolidated financial statements, and there are no overdue guarantees or litigation-related guarantee amounts [2]

英科医疗科技股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日、2025 年 5 月 26 日分别召开的第四届董事会第二次（定期） 会议、第四届监事会第二次（定期）会议以及 2024 年度股东大会， 审议通过了《关于公司及子公司向银行申请授信额度及担保事项的议 案》。为满足公司及子公司的生产经营需要，公司及子公司拟向银行 等金融机构申请综合授信的额度以及金融衍生品交易风险限额的总 额（以下简称"授信额度"）不超过 360 亿元人民币，对其担保总额 不超过 360 亿元人民币，授权期限自公司 2024 年度股东大会审议通 过之日起至下一年度股东大会召开时止。具体内容详见刊登于巨潮资 讯网（www.cninfo.com.cn）的《关于公司及子公司向银行申请授信额 度及担保事项的公告》《2024 年度股东大会决议公告》（公告编号： 2025-046、2025-072）。 一、担保事项概述 安庆英科医疗有限公司（以下简称"安庆英科"）因经营需要， 向中信银行股份有限公司安庆分行（以下简称"中信银行安庆分行"） 申请授信额度。公司为上述授信提供人民币 8,000 万元的连带责任保 证担保，并于近日与中信 ...